Earnings ·
Anika Therapeutics reported second quarter 2026 financial results with total revenue of $32.6 million, a 16% increase…
ANIKAnika Therapeutics, Inc.
Anika Therapeutics reported second quarter 2026 financial results with total revenue of $32.6 million, a 16% increase year-over-year. Commercial Channel revenue reached a record $13.9 million, up 17%, while OEM Channel revenue grew 14% to $18.7 million. The company achieved net income of $3.3 million and Adjusted EBITDA of $7.1 million, marking the highest Adjusted EBITDA since 2020. Gross margin expanded to 65%. Management raised full-year 2026 guidance, projecting total revenue growth of 5% to 10% and an Adjusted EBITDA margin of 13% to 17%. The company also revised its 2027 Commercial Channel revenue growth forecast to 5% to 15%, excluding potential Hyalofast revenue due to regulatory timing uncertainty. Anika Therapeutics operates in the medical device industry, specializing in osteoarthritis pain management and orthopedic regenerative solutions.